New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
09:05 EDTCLSN, RIMM, DD, CAT, JNJ, TRV, NUS, VZOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Travelers (TRV), up 3.5%... DuPont (DD), up 0.9%... ALSO HIGHER: Research In Motion (RIMM), up 7.1% after CEO reportedly says may license new BB10 operating system to other companies, upgrade to Outperform at Scotia Capital... Celsion (CLSN), up 11.4% after entering technology development agreement... DOWN AFTER EARNINGS: Verizon (VZ), down 0.9%... Johnson & Johnson (JNJ), down 0.9%... ALSO LOWER: Nu Skin (NUS), down 3.2% after NY Post says Dan Loeb's Third Point took "sizable" short position... Caterpillar (CAT), down 1.8% after announcing plans for $580M Q4 charge for accounting misconduct at unit.
News For TRV;DD;VZ;JNJ;RIMM;NUS;CAT;CLSN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 9, 2014
12:25 EDTVZOn The Fly: Midday Wrap
Subscribe for More Information
10:38 EDTVZVerizon CFO Shammo says not interested in doing large international M&A deal
CFO Fran Shammo sees wireless CapEx continuing to trend up, sees wireline CapEx continuing to trend down. Says does not believe wireless CapEx will decline. Shammo commented that ""The day we start to cut wireless CapEx is the day we start to wonder where the future of this industry is going." Says dividend policy "very important." Says doesn't see share buybacks until balance sheet is delevered.
10:28 EDTVZVerizon drops after warning about promotional impact on profits
Subscribe for More Information
10:27 EDTVZVerizon CFO says would sell towers for 'right price, right terms'
Subscribe for More Information
10:23 EDTTRVOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:23 EDTVZOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:17 EDTVZVerizon CFO Shammo says sees promotional pricing 'settling down' in 2015
Says Q4 has been a "pretty exciting" period, says seeing increase in activations, but seeing some increase in churn as well. Says has seen high volume in Q4 sales. Says continues to see strong momentum for wireless customer growth in Q4. Sees promotional pricing "settling down" in 2015. Shammo says social media, press has built this up as a price war; says rival's half-priced promotion "not as dramatic" as it looks. Says tablets a "tremendous" growth area for industry. Says streaming TV to mobile to begin in mid-2015. Says that over time, company believes can increase margins. Comments made at the UBS Global Media & Communications Conference. Verizon shares are down 3.8% to $47.04 in morning trading.
09:38 EDTVZActive equity options trading
Subscribe for More Information
07:40 EDTVZVerizon competition increased, company should be able to respond, says Canaccord
Subscribe for More Information
07:32 EDTVZUBS to hold a conference
Subscribe for More Information
06:54 EDTTRVTravelers initiated with a Neutral at JPMorgan
Subscribe for More Information
06:15 EDTVZVerizon downgraded at RW Baird
As previously reported, Baird downgraded Verizon to Neutral from Outperform. The firm downgraded shares citing last night's negative pre-announcement due to increasing competitive concerns, margin pressures, higher churn, and full valuation. Price target lowered to $50 from $54.
06:01 EDTVZVerizon downgraded to Neutral from Outperform at RW Baird
Subscribe for More Information
05:50 EDTJNJPharmacyclics data demonstrates safety, durability response
New, 27-month IMBRUVICA median follow-up data announced by Pharmacyclics (PCYC) support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma, or MCL, an aggressive type of lymphoma. More than 30% of IMBRUVICA patients remained progression-free after two years with no new or unexpected adverse events occurring during that time. Nearly half of the 111 patients treated were still living at the time of the data analysis. A second Phase II trial looked at IMBRUVICA's efficacy and safety as a single-agent treatment for MCL patients who previously had received rituximab combination therapy and at least two cycles of bortezomib. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:43 EDTJNJPharmacyclics reports IMBRUVICA data shows 84% PFS rate at one year
Pharmacyclics (PCYC) announced new, longer term data in IMBRUVICA patients with relapsed/refractory chronic lymphocytic leukemia, or CLL, including high-risk CLL patients with deletion 17p. Results from the Phase III RESONATE trial demonstrated an 84% progression-free survival, or PFS, rate in all patients with previously treated CLL or small lymphocytic lymphoma, or SLL, who received IMBRUVICA and a 94% PFS rate in patients who received only one prior therapy at 12 months. Separately, follow-up data was reported from Phase II RESONATE-17, or PCYC-1117, the largest prospective trial dedicated to studying CLL or SLL patients with del 17p. The data showed that IMBRUVICA was associated with an 83% overall response rate, or ORR, at a median follow up of 11.5 months. At 12 months, the estimated PFS was 79%. These results and additional data were presented here at the 56th American Society of Hematology, or ASH, Annual Meeting, highlighting IMBRUVICA's sustained efficacy in relapsed/refractory patients who have received at least one prior therapy. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:27 EDTJNJPharmacyclics IMBRUVICA Phase II combination data shows positive profile
Subscribe for More Information
December 8, 2014
18:24 EDTVZOn The Fly: After Hours Movers
Subscribe for More Information
17:05 EDTVZVerizon sees Q4 impacts of promotional offers will pressure wireless EBITDA, EPS
Subscribe for More Information
15:49 EDTNUSNu Skin to host investor day
Subscribe for More Information
14:31 EDTNUSNu Skin December volatility elevated into investor day
Nu Skin December weekly call option implied volatility is at 84, December is at 56, January is at 50, March is at 52; compared to its 26-week average of 48 according to Track Data, suggesting large near term price movement into company hosted investor day on December 12.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use